Browse FCGR2A

Summary
SymbolFCGR2A
NameFc fragment of IgG, low affinity IIa, receptor (CD32)
Aliases CD32A; Immunoglobulin G Fc receptor II; FCGR2A1; Fc fragment of IgG, low affinity IIa, receptor for (CD32); ......
Chromosomal Location1q23
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Basic function annotation.
> Subcellular Location, Domain and Function
> Gene Ontology
> KEGG and Reactome Pathway
> Subcellular Location, Domain and Function
 
Subcellular Location Cell membrane Single-pass type I membrane protein
Domain PF13895 Immunoglobulin domain
Function

Binds to the Fc region of immunoglobulins gamma. Low affinity receptor. By binding to IgG it initiates cellular responses against pathogens and soluble antigens. Promotes phagocytosis of opsonized antigens.

> Gene Ontology
 
Biological Process GO:0002429 immune response-activating cell surface receptor signaling pathway
GO:0002431 Fc receptor mediated stimulatory signaling pathway
GO:0002433 immune response-regulating cell surface receptor signaling pathway involved in phagocytosis
GO:0002757 immune response-activating signal transduction
GO:0002764 immune response-regulating signaling pathway
GO:0002768 immune response-regulating cell surface receptor signaling pathway
GO:0006909 phagocytosis
GO:0038093 Fc receptor signaling pathway
GO:0038094 Fc-gamma receptor signaling pathway
GO:0038096 Fc-gamma receptor signaling pathway involved in phagocytosis
Molecular Function GO:0019864 IgG binding
GO:0019865 immunoglobulin binding
Cellular Component -
> KEGG and Reactome Pathway
 
KEGG hsa04145 Phagosome
hsa04380 Osteoclast differentiation
hsa04611 Platelet activation
hsa04666 Fc gamma R-mediated phagocytosis
Reactome R-HSA-2029481: FCGR activation
R-HSA-2029480: Fcgamma receptor (FCGR) dependent phagocytosis
R-HSA-168256: Immune System
R-HSA-168249: Innate Immune System
R-HSA-6798695: Neutrophil degranulation
R-HSA-2029482: Regulation of actin dynamics for phagocytic cup formation
R-HSA-2029485: Role of phospholipids in phagocytosis
Summary
SymbolFCGR2A
NameFc fragment of IgG, low affinity IIa, receptor (CD32)
Aliases CD32A; Immunoglobulin G Fc receptor II; FCGR2A1; Fc fragment of IgG, low affinity IIa, receptor for (CD32); ......
Chromosomal Location1q23
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Literatures that report relations between FCGR2A and anti-tumor immunity. The specific mechanism were also collected if the literature reports that a gene specifically promotes or inhibits the infiltration or function of T/NK cells.
> Text Mining
 
  Literatures describing the relation between FCGR2A and anti-tumor immunity in human cancer.
PMID Cancer type Relation to immunity Evidence sentences
27742794Renal Cell CarcinomaPromote immunityFCGR Polymorphisms Influence Response to IL2 in Metastatic Renal Cell Carcinoma. Fc-gamma receptors (FCGRs) are expressed on immune cells, bind to antibodies, and trigger antibody-induced cell-mediated antitumor responses when tumor-reactive antibodies are present. The affinity of the FCGR/antibody interaction is variable and dependent upon FCGR polymorphisms. When higher-affinity genotypes for FCGR2A, FCGR3A, and FCGR2C were considered together, they were associated with significantly increased tumor shrinkage and prolonged survival in response to HD-IL2.
Summary
SymbolFCGR2A
NameFc fragment of IgG, low affinity IIa, receptor (CD32)
Aliases CD32A; Immunoglobulin G Fc receptor II; FCGR2A1; Fc fragment of IgG, low affinity IIa, receptor for (CD32); ......
Chromosomal Location1q23
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content High-throughput screening data (e.g. CRISPR-Cas9, shRNA and RNAi) for T cell-mediated killing. Genetic screen techniques can identify mechanisms of tumor cell resistance (e.g., PTPN2) and sensitivity (e.g., APLNR) to killing by cytotoxic T cells, the central effectors of anti-tumor immunity. After comprehensively searching, eight groups of screening data sets were collected in the current database. In this tab, users can check whether their selected genes cause resistance or increase sensitivity to T cell-mediated killing in various data sets.
> High-throughput Screening
  Statistical results of FCGR2A in screening data sets for detecting immune reponses.
PMID Screening System Cancer Type Cell Line Data Set Statistical Results Relation to immunity
29301958CRISPR-Cas9 melanomaB16F10Pmel-1 T cell NA/NSNA/NS
29301958CRISPR-Cas9 melanomaB16F10OT-1 T cell NA/NSNA/NS
28783722CRISPR-Cas9 melanomaMel6242CT-CRISPR NA/NSNA/NS
28723893CRISPR-Cas9 melanomaB16GVAX+Anti-PD1 NA/NSNA/NS
28723893CRISPR-Cas9 melanomaB16GVAX NA/NSNA/NS
25691366RNAiBreast cancerMCF7Luc-CTL assay NA/NSNA/NS
24476824shRNAmelanomaB16Primary screen NA/NSNA/NS
24476824shRNAmelanomaB16Secondary screen NA/NSNA/NS
Summary
SymbolFCGR2A
NameFc fragment of IgG, low affinity IIa, receptor (CD32)
Aliases CD32A; Immunoglobulin G Fc receptor II; FCGR2A1; Fc fragment of IgG, low affinity IIa, receptor for (CD32); ......
Chromosomal Location1q23
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Transcriptomic and genomic profiling of pre-treated tumor biopsies from responders and non-responders to immunotherapy. These data were used to identify signatures and mechanisms of response to checkpoint blockade (e.g., anti-PDL1 and anti-PD1). One example is that mutations in the gene PBRM1 benefit clinical survival of patients with clear cell renal cell carcinoma. After comprehensively searching, we collected 5 and 6 of transcriptomic and genomic data sets, respectively. In this tab, users can check whether their selected genes have significant difference of expression or mutation between responders and non-responders in various data sets.
> Expression difference between responders and non-responders
> Mutation difference between responders and non-responders
> Expression difference between responders and non-responders
 
Points in the above scatter plot represent the expression difference of FCGR2A in various data sets.
No PMID Cancer type Group Drug # Res # NRes Log2 (Fold Change) P value Anno
126997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)14120.4490.284
226997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)650.2990.9
326997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)870.5640.736
428552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 916-0.1420.803
528552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 59-1.0390.592
628552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 470.9990.704
729033130MelanomaallAnti-PD-1 (nivolumab) 2623-0.1220.819
829033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 1511-0.3020.875
929033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 11120.0950.964
1029301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 480.8380.628
1129301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 2001
1229301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 281.4130.61
1329443960Urothelial cancerallAnti-PD-L1 (atezolizumab) 68230-0.1360.455
> Mutation difference between responders and non-responders
 
Points in the above scatter plot represent the mutation difference of FCGR2A in various data sets.
No PMID Cancer type Group Drug # Res # NRes % Mut/Res % Mut/NRes % Diff (R vs NR) Pval Anno
125765070Non-small cell lung cancer (NSCLC)allAnti-PD-1 (pembrolizumab) 14170001
225765070Non-small cell lung cancer (NSCLC)smokingAnti-PD-1 (pembrolizumab) 1030001
325765070Non-small cell lung cancer (NSCLC)non-smokingAnti-PD-1 (pembrolizumab) 4140001
426359337MelanomaallAnti-CTLA-4 (ipilimumab) 277301.4-1.41
526359337MelanomaBRAFiAnti-CTLA-4 (ipilimumab) 0140001
626359337Melanomanon-BRAFiAnti-CTLA-4 (ipilimumab) 275901.7-1.71
726997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)211705.9-5.90.447
826997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)860001
926997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)131109.1-9.10.458
1028552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 91611.16.24.91
1128552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 590001
1228552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 472514.310.71
1329033130MelanomaallAnti-PD-1 (nivolumab) 38275.33.71.61
1429033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 22134.504.51
1529033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 16146.27.1-0.91
1629301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 11130001
1729301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 610001
1829301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 5120001
Summary
SymbolFCGR2A
NameFc fragment of IgG, low affinity IIa, receptor (CD32)
Aliases CD32A; Immunoglobulin G Fc receptor II; FCGR2A1; Fc fragment of IgG, low affinity IIa, receptor for (CD32); ......
Chromosomal Location1q23
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between abundance of tumor-infiltrating lymphocytes (TILs) and expression, copy number, methylation, or mutation of FCGR2A. The immune-related signatures of 28 TIL types from Charoentong's study, which can be viewed in the download page. For each cancer type, the relative abundance of TILs were inferred by using gene set variation analysis (GSVA) based on gene expression profile. In this tab, users can examine which kinds of TILs might be regulated by the current gene.
> Lymphocyte
 
Summary
SymbolFCGR2A
NameFc fragment of IgG, low affinity IIa, receptor (CD32)
Aliases CD32A; Immunoglobulin G Fc receptor II; FCGR2A1; Fc fragment of IgG, low affinity IIa, receptor for (CD32); ......
Chromosomal Location1q23
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between three kinds of immunomodulators and expression, copy number, methylation, or mutation of FCGR2A. These immunomo-dulators were collected from Charoentong's study. In this tab, users can examine which immunomodulators might be regulated by FCGR2A.
> Immunoinhibitor
> Immunostimulator
> MHC molecule
> Immunoinhibitor
 
> Immunostimulator
 
> MHC molecule
 
Summary
SymbolFCGR2A
NameFc fragment of IgG, low affinity IIa, receptor (CD32)
Aliases CD32A; Immunoglobulin G Fc receptor II; FCGR2A1; Fc fragment of IgG, low affinity IIa, receptor for (CD32); ......
Chromosomal Location1q23
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between chemokines (or receptors) and expression, copy number, methylation, or mutation of FCGR2A. In this tab, users can examine which chemokines (or receptors) might be regulated by the current gene.
> Chemokine
> Receptor
> Chemokine
 
> Receptor
 
Summary
SymbolFCGR2A
NameFc fragment of IgG, low affinity IIa, receptor (CD32)
Aliases CD32A; Immunoglobulin G Fc receptor II; FCGR2A1; Fc fragment of IgG, low affinity IIa, receptor for (CD32); ......
Chromosomal Location1q23
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Distribution of FCGR2A expression across immune and molecular subtypes.
> Immune subtype
> Molecular subtype
> Immune subtype
 
> Molecular subtype
 
Summary
SymbolFCGR2A
NameFc fragment of IgG, low affinity IIa, receptor (CD32)
Aliases CD32A; Immunoglobulin G Fc receptor II; FCGR2A1; Fc fragment of IgG, low affinity IIa, receptor for (CD32); ......
Chromosomal Location1q23
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Associations between FCGR2A and clinical features.
> Overall survival analysis
> Cancer stage
> Tumor grade
> Overall survival
 
> Stage
 
> Grade
 
Summary
SymbolFCGR2A
NameFc fragment of IgG, low affinity IIa, receptor (CD32)
Aliases CD32A; Immunoglobulin G Fc receptor II; FCGR2A1; Fc fragment of IgG, low affinity IIa, receptor for (CD32); ......
Chromosomal Location1q23
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Drugs targeting FCGR2A collected from DrugBank database.
> Drugs from DrugBank database
 

  Details on drugs targeting FCGR2A.
ID Name Drug Type Targets #Targets
DB00002CetuximabBiotechC1QA, C1QB, C1QC, C1R, C1S, EGFR, FCGR1A, FCGR2A, FCGR2B, FCGR2C, ......12
DB00005EtanerceptBiotechC1QA, C1QB, C1QC, C1R, C1S, FCGR1A, FCGR2A, FCGR2B, FCGR2C, FCGR3A ......14
DB00028Immune Globulin HumanBiotechC3, C4A, C4B, C5, FCGR1A, FCGR1B, FCGR2A, FCGR2B, FCGR2C, FCGR3A, ......11
DB00051AdalimumabBiotechC1QA, C1QB, C1QC, C1R, C1S, FCGR1A, FCGR2A, FCGR2B, FCGR2C, FCGR3A ......12
DB00054AbciximabBiotechC1QA, C1QB, C1QC, C1R, C1S, FCGR1A, FCGR2A, FCGR2B, FCGR2C, FCGR3A ......14
DB00056Gemtuzumab ozogamicinBiotechC1QA, C1QB, C1QC, C1R, C1S, CD33, FCGR1A, FCGR2A, FCGR2B, FCGR2C, ......12
DB00072TrastuzumabBiotechC1QA, C1QB, C1QC, C1R, C1S, EGFR, ERBB2, FCGR1A, FCGR2A, FCGR2B, F ......13
DB00073RituximabBiotechC1QA, C1QB, C1QC, C1R, C1S, FCGR1A, FCGR2A, FCGR2B, FCGR2C, FCGR3A ......12
DB00074BasiliximabBiotechC1QA, C1QB, C1QC, C1R, C1S, FCGR1A, FCGR2A, FCGR2B, FCGR2C, FCGR3A ......13
DB00075MuromonabBiotechC1QA, C1QB, C1QC, C1R, C1S, CD247, CD3D, CD3E, CD3G, FCGR1A, FCGR2 ......15
DB00078Ibritumomab tiuxetanBiotechC1QA, C1QB, C1QC, C1R, C1S, FCGR1A, FCGR2A, FCGR2B, FCGR2C, FCGR3A ......12
DB00081TositumomabBiotechC1QA, C1QB, C1QC, C1R, FCGR1A, FCGR2A, FCGR2B, FCGR2C, FCGR3A, FCG ......11
DB00087AlemtuzumabBiotechC1QA, C1QB, C1QC, C1R, CD52, FCGR1A, FCGR2A, FCGR2B, FCGR2C, FCGR3 ......11
DB00092AlefaceptBiotechC1QA, C1QB, C1QC, C1R, CD2, FCGR1A, FCGR2A, FCGR2B, FCGR2C, FCGR3A ......11
DB00095EfalizumabBiotechC1QA, C1QB, C1QC, C1R, FCGR1A, FCGR2A, FCGR2B, FCGR2C, FCGR3A, FCG ......11
DB00108NatalizumabBiotechC1QA, C1QB, C1QC, C1R, FCGR1A, FCGR2A, FCGR2B, FCGR2C, FCGR3A, FCG ......12
DB00110PalivizumabBiotechC1QA, C1QB, C1QC, C1R, FCGR1A, FCGR2A, FCGR2B, FCGR2C, FCGR3A, FCG ......10
DB00111DaclizumabBiotechC1QA, C1QB, C1QC, C1R, FCGR1A, FCGR2A, FCGR2B, FCGR2C, FCGR3A, FCG ......12
DB00112BevacizumabBiotechC1QA, C1QB, C1QC, C1R, FCGR1A, FCGR2A, FCGR2B, FCGR2C, FCGR3A, FCG ......11
DB06607CatumaxomabBiotechCD3E, EPCAM, FCGR1A, FCGR2A, FCGR3A, FCGR3B6
DB11767SarilumabBiotechFCGR1A, FCGR2A, FCGR2B, FCGR3A, FCGR3B, IL6R6